Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.

Clinical lung cancer - 1 Jul 2010

Wu Jenn-Yu, Yang Chih-Hsin, Hsu Ya-Chieh, Yu Chong-Jen, Chang Shih-Han, Shih Jin-Yuan, Yang Pan-Chyr

Abstract excerpt

BACKGROUND: Gefitinib and cetuximab are both epidermal growth factor receptor (EGFR) target therapies used to treat patients with non-small-cell lung cancer (NSCLC) with different mechanisms. To clarify the effectiveness of cetuximab after failure of gefitinib treatment, we investigated the clinical features of patients with NSCLC who received cetuximab-containing chemotherapy after failure of gefitinib. PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Quinazolines

Share to ras Proteins

Share to Remission Induction

Share to Salvage Therapy

Share to Treatment Failure

Source

Identifiers

PMID: 20630828
DOI: 10.3816/CLC.2010.n.033

Genes

EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.PMID 20630828Read ↗

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].Semantic proximity Read ↗

[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].Semantic proximity Read ↗

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.Semantic proximity Read ↗

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.Semantic proximity Read ↗

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.Semantic proximity Read ↗

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.Semantic proximity Read ↗

An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.